Other phase III studies, MONALEESA-2 and MONARCH-3, and the phase II PALOMA-1 study demonstrated a PFS benefit for CDK4/6 inhibitors in HR+/HER2- advanced breast cancer (Table 1), but they all excluded patients with brain metastases; unfortunately, sites of disease progression were not available in these studies [1]. Here, CDK4 is linked to breast cancer.